Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Evercore ISI

Evercore ISI assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN - Free Report) in a research report report published on Thursday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $46.00 price objective on the stock.

A number of other equities analysts have also recently issued reports on DYN. Scotiabank began coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective for the company. HC Wainwright cut their price objective on Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. Chardan Capital restated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, May 9th. Piper Sandler reduced their price target on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Finally, BMO Capital Markets started coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.15.

Dyne Therapeutics Price Performance

NASDAQ DYN traded down $0.42 during trading on Thursday, reaching $11.82. The company's stock had a trading volume of 1,132,995 shares, compared to its average volume of 1,630,026. The stock has a market capitalization of $1.34 billion, a PE ratio of -3.32 and a beta of 1.19. The firm has a fifty day moving average of $10.30 and a 200 day moving average of $16.33. Dyne Therapeutics has a one year low of $6.36 and a one year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). Research analysts expect that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Trading of Dyne Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in Dyne Therapeutics by 0.3% in the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock worth $5,532,000 after acquiring an additional 698 shares during the period. Summit Investment Advisors Inc. lifted its stake in Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after acquiring an additional 721 shares during the period. KBC Group NV lifted its stake in Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock worth $74,000 after acquiring an additional 978 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Dyne Therapeutics by 5.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock worth $237,000 after acquiring an additional 1,115 shares during the period. Finally, E Fund Management Co. Ltd. lifted its stake in Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after acquiring an additional 1,249 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.